{"groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"FG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"FG001","title":"Arm B"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"257"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"257"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}